By removing contaminants and improving the quality of mRNA, Cisterna Biologics seeks to develop high-quality mRNA for therapeutic applications. Their goal is to reduce the cost of mRNA manufacturing and potentially enhance its quality by expressing and purifying mRNA directly from a eukaryotic host. This approach could lead to more effective and accessible treatments for patients worldwide. Founded in 2022 and based in Carlsbad, California, Cisterna Biologics is focused on developing mRNA-based therapeutics for gene therapies.